MaineCare does not cover Wegovy or Zepbound for weight loss

MaineCare's preferred drug list states that weight loss drugs are not covered. Wegovy (injection and tablets) is a preferred drug only to lower the risk of major cardiovascular events or, for the injection, to treat MASH, with clinical prior authorization, and the prior authorization form says MaineCare policy does not allow coverage for weight loss products. Zepbound is non-preferred and is covered only for moderate to severe obstructive sleep apnea.12357

Wegovy needs a clinical prior authorization on MaineCare form 23976 to establish a cardiovascular or MASH diagnosis; initial approvals last 3 months. Zepbound for sleep apnea uses the general non-preferred form 20420.23456

• Wegovy, cardiovascular path: adult with a BMI over 27, not used for weight loss only, with a history of stroke, heart attack or symptomatic peripheral arterial disease documented in chart notes; the form also asks whether the patient takes a lipid-lowering drug and for a current A1C.
• Wegovy, MASH path (injection only): MASH with stage F2 or F3 liver fibrosis shown by a combination of non-invasive tests or a biopsy, no decompensated cirrhosis, and prescribed by or with a gastroenterologist, hepatologist or endocrinologist.
• Zepbound, sleep apnea path: adult with a BMI of 30 or more and moderate to severe obstructive sleep apnea confirmed by a sleep study in the last 3 years (AHI of 15 or more), CPAP that is ineffective or not tolerated for at least 90 days, and at least 3 months of lifestyle changes without enough weight loss; not for patients with type 1 or type 2 diabetes.
• Ozempic (non-preferred for diabetes): preferred incretin mimetics must be tried and fail first, in step order, unless a clinical exception is documented.

Coverage for other uses the FDA has approved:

• Wegovy (injection), reduction of the risk of major adverse cardiovascular events in adults with a BMI over 27 and a history of stroke, heart attack or symptomatic peripheral arterial disease (injection and tablets): Covered with prior authorization257
• Wegovy (injection), MASH with moderate to advanced (F2 to F3) liver fibrosis, injection only: Covered with prior authorization257
• Zepbound, moderate to severe obstructive sleep apnea in adults with a BMI of 30 or more, without diabetes: Covered with prior authorization39

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page names no participating states, and we found no MaineCare announcement that Maine has joined.14

Since July 1, 2026, State of Maine Health Plan members who take a GLP-1 for weight loss must enroll in Virta Health and get the prescription from a Virta provider to keep coverage. After Oct. 30, 2026, weight-loss GLP-1 prescriptions filled outside Virta are not covered. The rule applies only to GLP-1s prescribed for weight loss.151617

Pharmacy benefit: Judi Rx, formerly Capital Rx (pharmacy); Anthem Blue Cross and Blue Shield (medical).

Marketplace (ACA) plans: Maine's essential health benefits benchmark plan, an Anthem Blue Cross and Blue Shield small-group Blue Choice plan, excludes prescription drugs for weight reduction.20

On the incretin mimetic list of the October 1, 2026 PDL, Rybelsus, Trulicity and Victoza are preferred and Ozempic is non-preferred (step 6). A non-preferred drug is approved only after preferred drugs are tried and fail in step order, unless a clinical exception applies. Mounjaro does not appear on the PDL since July 1, 2026.411

In 2025, MaineCare paid for 41,253 GLP-1 prescriptions, $40.4 million before rebates: 29 per 1,000 residents, against 32 across the states and DC, 20th of 51.68 It reimbursed 7 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 16 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.4344343530382333

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.3031322338394041423736
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.252723

In 2024, Medicare Part D drug plans paid for 104,905 GLP-1 claims from prescribers in Maine, $131.4 million in total drug cost.69

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.73 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check Maine on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7475 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

We found no action on compounded GLP-1s by Maine’s board of pharmacy or attorney general on their own sites.21

The FDA’s register lists 0 outsourcing facilities (503B) in Maine, as of November 6, 2026.70